Product Highlight - Evenity

Build bone first for your patients at very high fracture risk

• Recommended as the 1^st line therapy for patients with very high risk of fractures¹
• Significant BMD improvements vs teriparatide in 1 year of therapy²
• Reduced hip, vertebral, and non-vertebral fractures vs alendronate^*3
• Convenient monthly subcutaneous administration⁴

*In the ARCH study, patients receiving 1 year of romosozumab followed by 2 years of alendronate significantly reduced hip, vertebral, and non-vertebral fractures vs patients receiving 3 years of alendronate alone.


References:
1. Camacho PM, Petak SM, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis- 2020 Update. Endocr Pract. 2020; 26(5): 564-570.
2. Langdahl BL, Libanati C, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017; 390(10102): 1585-1594.
3. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017; 377(15): 1417-1427.
4. Evenity HK prescribing information. March 2020.

HK-08489-EVE-2022-Jun